ADMA BiologicsADMA -0.54%64 Market Cap is $2,123.0 Mil as of Jul. 08, 2026. GuruFocus rates ADMA with a GF Score™ of 64/100 and a GF Value™ of $18.04 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 1,420 Biotechnology companies, ADMA Biologics ranks better than 88.8% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). ADMA Biologics's share price for the quarter that ended in Mar. 2026 was $9.01. ADMA Biologics's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 232.3 Mil. Therefore, ADMA Biologics's market cap for the quarter that ended in Mar. 2026 was $2,092.9 Mil.
ADMA Biologics's quarterly market cap
increased
from Sep. 2025 ($3,493.9 Mil) to Dec. 2025 ($4,338.8 Mil) but then
declined
from Dec. 2025 ($4,338.8 Mil) to Mar. 2026 ($2,092.9 Mil).
ADMA Biologics's annual market cap
increased
from Dec. 2023 ($1,021.8 Mil) to Dec. 2024 ($4,058.1 Mil) and
increased
from Dec. 2024 ($4,058.1 Mil) to Dec. 2025 ($4,338.8 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. ADMA Biologics's Enterprise Value for Today is $2,189.3 Mil.
ADMA Biologics (NAS:ADMA) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
ADMA Biologics Market Cap Related Terms
ADMA Biologics Market Cap Historical Data
* Premium members only.
The historical data trend for ADMA Biologics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, ADMA Biologics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ADMA Biologics Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ADMA Biologics's Market Cap distribution charts can be found below:
* The bar in red indicates where ADMA Biologics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
ADMA Biologics's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADMA Biologics (ADMA) has a Market Cap of $2,123.0 Mil as of Jul. 08, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on ADMA Biologics and its competitors. According to the industry distribution chart, ADMA Biologics ranks #159 out of 1420 companies in the Biotechnology industry, placing it in the top 11.2%.
Is ADMA Biologics' Market Cap too high?
ADMA Biologics' current Market Cap is $2,123.0 Mil. The Biotechnology industry median Market Cap is 121.52. ADMA Biologics' value of $2,123.0 Mil is 1647.1% above this industry median. Based on the distribution chart, ADMA Biologics ranks #159 out of 1420 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, ADMA Biologics has a GF Score™ of 64/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ADMA Biologics' Market Cap compare to ZLAB and HRMY?
According to the Biotechnology industry distribution chart, ADMA Biologics ranks #159 out of 1420 companies for Market Cap. This places ADMA Biologics in the top 11% of its industry — outperforming the majority of peers. The industry median Market Cap is 121.52. ADMA Biologics' value of $2,123.0 Mil is 1647.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 121.52, based on 1,420 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ADMA Biologics's current Market Cap of $2,123.0 Mil is 1647.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on ADMA Biologics and its competitors. For the Biotechnology industry, the median Market Cap is 121.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ADMA Biologics's current Market Cap is $2,123.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADMA Biologics stock overvalued right now?
Based on GuruFocus' analysis, ADMA Biologics (ADMA) is currently considered Significantly Undervalued. The stock's GF Value™ is $18.04, compared to a current price of $9.16 — trading 49.2% below its estimated fair value. The current Market Cap is $2,123.0 Mil and 1647.1% above the Biotechnology industry median of 121.52. ADMA Biologics' overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For ADMA Biologics (ADMA), the current Market Cap is $2,123.0 Mil as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ADMA Biologics (ADMA) Overvalued in 2026?
Based on GuruFocus' analysis, ADMA Biologics stock appears to be undervalued.
The current stock price of $9.16 is trading 49.2% below its estimated GF Value™ of $18.04.
GuruFocus considers ADMA Biologics to be Significantly Undervalued.
Key valuation signals for ADMA:
Market Cap: $2,123.0 Mil
GF Value™: $18.04 vs. price of $9.16 (49.2% below fair value)
Industry Position: 1647.1% above the Biotechnology median (#159 of 1420)
No single metric tells the full story. See the ADMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
64GF Score
Get the complete analysis for ADMA
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADMA has been successfully added to your 
